SynthesisDiabetologia2022

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.

Thomas Karagiannis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.